Article
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
Japanese journal of clinical oncology - 1 Nov 2013
Nishina Tomohiro, Takano Yoshinao, Denda Tadamichi, Yasui Hisateru, Takeda Koji, Ura Takashi, Esaki Taito, Okuyama Yusuke, Kondo Ken, Takahashi Yasuo, Sugiyama Yasuyuki, Muro Kei
Abstract excerpt
OBJECTIVE: In Japan, there had been no prospective clinical studies conducted in terms of modified FOLFOX6 + bevacizumab therapy. We performed a post-marketing Phase II multicenter clinical study to examine the efficacy and safety of this regimen as first-line therapy for Japanese patients with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.